StockData
AstraZeneca PLC logo

AstraZeneca PLC

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca Strensiq (asfotase alfa) — Europe product sales by Quarter

Strensiq (asfotase alfa) — Europe product sales ($M) ($M)

QuarterlyAnnual

AstraZeneca Strensiq (asfotase alfa) — Europe product sales: $37M in Q2 2026, up 19.4% from a year earlier. That is the highest of the 20 quarters on record here.

Latest, Q2 2026
37
Period ended Jun 30, 2026
Change on a year earlier
+19.4%
31 in Q2 2025
History
20 quarters
Since Q3 2021
Sources
20
Documents cited below

Where the Q2 2026 figure comes from

“|| Strensiq | | 536 | | 36 | | 36 | | 452 | | 42 | | 16 | | 2 | | 2 | | 37 | | 20 | | 14 | | 31 | | 7 | | 15”

Source: Form 6-K FY2026Q2 Earnings Release ↗

Reported in Form 6-K / 20-F Product Sales Table.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedStrensiq (asfotase alfa) — Europe product sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 202637+19.4%Form 6-K FY2026Q2 Earnings Release ↗
Q1 2026Mar 31, 202632+23.1%Form 6-K FY2026Q1 Earnings Release ↗
Q4 2025Dec 31, 202534+30.8%Form 6-K FY2025Q4 Earnings Release ↗
Q3 2025Sep 30, 202532+28.0%Form 6-K FY2025Q3 Earnings Release ↗
Q2 2025Jun 30, 202531+29.2%Form 6-K FY2025Q2 Earnings Release ↗
Q1 2025Mar 31, 202526+8.3%Form 6-K FY2025Q1 Earnings Release ↗
Q4 2024Dec 31, 202426+4.0%Form 6-K FY2024Q4 Earnings Release ↗
Q3 2024Sep 30, 202425+13.6%Form 6-K FY2024Q3 Earnings Release ↗
Q2 2024Jun 30, 202424+14.3%Form 6-K FY2024Q2 Earnings Release ↗
Q1 2024Mar 31, 202424+14.3%Form 6-K FY2024Q1 Earnings Release ↗
Q4 2023Dec 31, 202325+31.6%Form 6-K FY2023Q4 Earnings Release ↗
Q3 2023Sep 30, 202322+22.2%Form 6-K FY2023Q3 Earnings Release ↗
Q2 2023Jun 30, 2023210.0%Form 6-K FY2023Q2 Earnings Release ↗
Q1 2023Mar 31, 202321+10.5%Form 6-K FY2023Q1 Earnings Release ↗
Q4 2022Dec 31, 202219-5.0%Form 6-K FY2022Q4 Earnings Release ↗
Q3 2022Sep 30, 202218+12.5%Form 6-K FY2022Q3 Earnings Release ↗

Breakdown

What makes up strensiq (asfotase alfa) — Europe product sales

Cite this data

StockData. (2026). AstraZeneca Strensiq (asfotase alfa) — Europe product sales ($M), quarterly Q3 2021–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-strensiq-eu

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.